Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Myeloproliferative neoplasms

Published in: Health & Medicine


  1. 2. Myeloproliferative Neoplasms (MPN) Ahmed Elshebiny, MD University of Menoufyia
  2. 3. Case <ul><li>66 y old woman with mild hypertension </li></ul><ul><li>Experienced TIA affecting her speech which resolved completely after 3 hours </li></ul><ul><li>Smoker </li></ul><ul><li>Normal liver and kidney functions </li></ul><ul><li>High hemoglobin =18 gm/dl </li></ul><ul><li>Decreased Epo level and JAK 2gene mutation </li></ul>
  3. 4. Case cont. <ul><li>Hb 18 gm/dl </li></ul><ul><li>Leukocytes 12,500/cu mm </li></ul><ul><li>Thrombocytes 400,000/cu mm </li></ul><ul><li>Hct 58% </li></ul><ul><li>O2 saturation (arterial) 94% </li></ul><ul><li>Serum erythropoietin Undetectable </li></ul><ul><li>Erythrocytes and leukocytes were immature in the peripheral blood smear. </li></ul><ul><li>Spleen was enlarged. </li></ul>
  4. 6. Hematological malignancies <ul><li>Hematological malignancies are defined and distinguished from one another essentially according to 4 parameters: </li></ul><ul><li>Clinical features </li></ul><ul><li>microscopic morphology </li></ul><ul><li>immunophenotype </li></ul><ul><li>molecular/genetic features. </li></ul>
  5. 8. Malignant cells <ul><li>Cell adhesion altered – cells able to move </li></ul><ul><li>Changes in structure of nucleus </li></ul><ul><li>Secretion of enzymes that enable them to invade neighboring tissues </li></ul><ul><li>Secretion of substances that inhibit normal cell proliferation </li></ul><ul><li>Unlimited number of cell divisions </li></ul><ul><li>Growth in the absence of appropriate signals </li></ul><ul><li>Avoidance of cell death (apoptosis) </li></ul>
  6. 9. Hematology lectures Myeloproliferative neoplasms
  7. 10. Myeloproliferative neoplasms (MPN) <ul><li>Chronic clonal hematopoetic stem cell diseases characterized by overproduction of one or more cell lines </li></ul><ul><li>Unlike myelodysplssia, the MPNs are associated with normal cell maturation and effective hematopoiesis </li></ul>
  8. 11. Epidemiology <ul><li>Most cases encountered in clinical practice are in patients aged 40-60 years. </li></ul><ul><li>Myeloproliferative diseases are uncommon in people younger than 20 years and are rare in childhood. </li></ul>
  9. 12. Etiology <ul><li>the precise cause of myeloproliferative disease is unknown. </li></ul><ul><li>The etiology is complex, incompletely understood, and likely a multistep process involving more than one gene. </li></ul>
  10. 13. Genetic abnormalities <ul><li>JAK 2 V617F mutation </li></ul><ul><li>Philadelphia chromosome </li></ul><ul><li>BCR-ABL </li></ul><ul><li>others </li></ul>
  11. 15. Symptoms <ul><li>Non specific of fatigue, wt loss, tennitus, vertigo </li></ul><ul><li>Abdominal discomfort and early satiety secondary to  splenomegaly </li></ul><ul><li>Bleeding </li></ul><ul><li>Thrombosis </li></ul><ul><li>Abdominal pain </li></ul><ul><li>Gout </li></ul>
  12. 16. <ul><li>CBC, film </li></ul><ul><li>Bone marrow </li></ul><ul><li>Cytogenetics </li></ul><ul><li>Polymerase chain reaction (PCR) or fluorescent in-situ hybridization (FISH) run on peripheral blood or bone marrow </li></ul><ul><li>LAP score </li></ul><ul><li>Red cell mass </li></ul><ul><li>Uric acid </li></ul>
  13. 17. ET
  14. 18. Myelofibrosis showing Leukoerythroblastic reaction
  15. 19. CML
  16. 20. Hyperviscosity syndrome <ul><li>Increased serum viscosity usually results from increased circulating serum immunoglobulins. </li></ul><ul><li>It can also result from increased cellular blood components in hyperproliferative states such as the leukemias, polycythemia, and the myeloproliferative disorders. </li></ul><ul><li>Clinically </li></ul><ul><li>Diagnosis </li></ul><ul><li>TTT </li></ul>
  17. 21. Polythycemia Vera Myeloproliferative neoplasms
  18. 22. Polythycemia vera( bone marrow)
  19. 23. Pathophysiology <ul><li>Normal stem cells are present in the bone marrow of patients with PV. </li></ul><ul><li>Also present are abnormal clonal stem cells that interfere with or suppress normal stem cell growth and maturation. </li></ul>
  20. 24. Pathophysiology cont. <ul><li>Mutation, or change, in the body's JAK2 gene </li></ul><ul><li>The JAK2 gene makes an important protein that helps the body produce blood cells </li></ul><ul><li>Usually this is not a genetic disease, but in some families, the gene may be more inclined to mutate </li></ul>
  21. 25. JAK 2 mutation
  22. 26. Clinical suspicion <ul><li>Polycythemia vera should be suspected in patients with elevated hemoglobin or hematocrit levels, splenomegaly, or portal venous thrombosis. </li></ul>
  23. 27. Manifestations <ul><li>Insidious </li></ul><ul><li>Tirdeness , verigo, visual disturbances </li></ul><ul><li>HTN </li></ul><ul><li>Angina </li></ul><ul><li>Cl;audications </li></ul><ul><li>Tendancy to bleeding or thrombosis </li></ul><ul><li>Itching </li></ul><ul><li>Peptic ulcer </li></ul><ul><li>Plethora </li></ul><ul><li>Conjunctival injection </li></ul><ul><li>Splenomegaly(70%) </li></ul><ul><li>Hepatomegaly(50%) </li></ul>
  24. 28. Course <ul><li>Untreated patients may survive for six to 18 months, whereas adequate treatment may extend life expectancy to more than 10 years. </li></ul><ul><li>Fate </li></ul><ul><ul><li>Myelofibrosis </li></ul></ul><ul><ul><li>Acute leukemia </li></ul></ul><ul><ul><li>Complications </li></ul></ul>
  25. 29. DD <ul><li>Causes of polycythemia </li></ul><ul><li>Other MPN </li></ul><ul><li>Causes of </li></ul>
  26. 30. Acquired Secondary polythycemia <ul><li>Epo-mediated </li></ul><ul><ul><li>Hypoxia-driven </li></ul></ul><ul><ul><ul><li>Central hypoxic process </li></ul></ul></ul><ul><ul><ul><ul><li>Chronic lung dz, R to L shunt, high altitude, CO poisoning, hypoventilation </li></ul></ul></ul></ul><ul><ul><ul><li>Peripheral hypoxic process - renal artery stenosis </li></ul></ul></ul><ul><ul><li>Hypoxia-independent (pathologic epo production) </li></ul></ul><ul><ul><ul><li>Malignant tumors </li></ul></ul></ul><ul><ul><ul><ul><li>Hepatoma, renal cell, cerebellar hemangioblastoma, parathyroid carcinoma </li></ul></ul></ul></ul><ul><ul><ul><li>Non-malignant tumors </li></ul></ul></ul><ul><ul><ul><ul><li>Fibroids, renal cysts, pheo, meningioma </li></ul></ul></ul></ul><ul><li>Drug Associated - epo, androgens </li></ul><ul><li>Unknown mechanism - post-renal transplant erythrocytosis </li></ul>
  27. 31. Essential thrombocythemia (ET) Myeloproliferative neoplasms
  28. 32. Essential Thrombocythemia <ul><li>50% have JAK 2 mutation </li></ul><ul><li>Incidence is similar to P vera </li></ul><ul><li>20% of pts are <40 y.o. </li></ul>
  29. 33. Diagnosis <ul><li>First, rule out secondary causes of thrombocytosis: cancer, infection, inflammation, bleeding, iron deficiency </li></ul><ul><li>Pts may have splenomegaly </li></ul><ul><li>Platelet count should be >600 on 2 separate occasions, at least 1 month apart </li></ul><ul><li>Exclude CML by absence of Philadelphia chromosome </li></ul><ul><li>Exclude P vera by nl hemoglobin without iron deficiency. </li></ul>
  30. 34. Reactive thrombocythemia <ul><li>Autoimmune rheumatic disorders </li></ul><ul><li>Malignancy </li></ul><ul><li>Splenectomy </li></ul>
  31. 35. Primary Myelofibrosis Myeloproliferative neoplasms
  32. 36. Myelofibrosis <ul><li>agnogenic myeloid metaplasia with myelofibrosis </li></ul><ul><li>Clonal stem cell disorder affecting megakaryocytes predominantly </li></ul><ul><li>All myeloproliferative disorders can result in a spent phase which can be difficult to distinguish from primary MF </li></ul><ul><li>Myeloid metaplasia refers to earlier proliferative phase where extramedullary hematopoiesis predominates. </li></ul>
  33. 37. Myelofibrosis
  34. 38. Myelofibrosis <ul><li>Natural History </li></ul><ul><ul><li>Median survival is 5 yrs </li></ul></ul><ul><ul><li>Transforms into AML in 5-20% </li></ul></ul><ul><li>Symptoms </li></ul><ul><ul><li>>50% pts present with sx of anemia and thrombocytopenia </li></ul></ul><ul><ul><li>Pts may have fever, sweats, wt loss </li></ul></ul><ul><ul><li>As spleen enlarges (from EMH), pts may have abdominal pain, early satiety. </li></ul></ul>
  35. 39. Lab finding in myelofibrosis <ul><li>Early on, pts may have  Plts and nl Hgb and WBC. </li></ul><ul><li>Anemia, and  Plts and  WBC seen as disease progresses </li></ul><ul><li>Peripheral smear shows leukoerythroblastic picture, with teardrops, NRBC and early granulocytes </li></ul><ul><li>“ Dry tap” or inability to aspirate liquid marrow frequently seen </li></ul><ul><li>Increased collagen and reticulin fibrosis on BM biopsy </li></ul><ul><li>40-75% may have JAK2 mutation </li></ul>
  36. 40. Treatment Myeloproliferative neoplasms
  37. 41. TTT of Polycythemia Vera <ul><li>Therapeutic phlebotomies alone to maintain hematocrit level at less than 45%. </li></ul><ul><li>Myelosupressive therapy(Hydroxyurea) </li></ul><ul><li>An alternative therapy in older patients is radioactive phosphorous (32P), but this is unsuitable for younger patients because of the potential for causing secondary leukemia. </li></ul>
  38. 42. Hydroxyurea <ul><li>Antineoplastic agent provides effective palliative treatment that primarily controls symptoms associated with leukocytosis, thrombocytosis, or hepatosplenomegaly due to MPD. </li></ul><ul><li>Inhibitor of deoxynucleotide synthesis </li></ul><ul><li>Less leukemogenic </li></ul><ul><li>Uses </li></ul>
  39. 43. Treatment of ET <ul><li>The aim of treatment is to maintain the platelet count within the reference range. </li></ul><ul><li>This usually can be achieved by </li></ul><ul><ul><ul><li>hydroxyurea </li></ul></ul></ul><ul><ul><ul><li>or anagrelide. </li></ul></ul></ul><ul><ul><ul><li>Interferon -alpha </li></ul></ul></ul>
  40. 44. Treatment of myelofibrosis <ul><li>No curative treatment is available at the present time. </li></ul><ul><li>Conservative, Epo </li></ul><ul><li>Hydroxyurea </li></ul><ul><li>Splenic irradiation therapy </li></ul><ul><li>Splenectomy </li></ul><ul><li>Allogenic bone marrow transplantation </li></ul><ul><li>? Bisphosphonates </li></ul>
  41. 45. Treatment of CML <ul><li>HSCT </li></ul><ul><li>Imatinib </li></ul><ul><li>Dasatinib </li></ul><ul><li>Interferone </li></ul><ul><li>Cytosine arabinoside </li></ul><ul><li>Hydroxyurea </li></ul><ul><li>When the disease progresses to the blast phase treat as acute leukemia </li></ul>
  42. 46. References <ul><li>Bethesda Handbook of Clinical hematology 2010 </li></ul><ul><li>Hamilton et al : Hematology in Clinical practice 2005 </li></ul><ul><li>E-medicine online textbook, Hematology </li></ul><ul><li>Other web resources </li></ul>
  43. 47. THANK YOU